|
The Indian medical technology sector is poised for a major transformation with the launch of MedArtha Capital, the nation’s first dedicated Rs.1,000 crore growth fund focused exclusively on medtech.
This landmark initiative, spearheaded by industry veteran Ganesh Sabat, aims to provide a critical financial boost to growth-stage domestic manufacturers, marking a defining moment in India’s quest for self-reliance in healthcare technology.
According to Dr CS Satheesh Kumar, former Drug Controller of Kerala and currently a senior officer in the medical devices industry in Ernakulam, the fund arrives at a time when India remains heavily dependent on imports for nearly 80 percent of its medical devices. By targeting companies with annual revenues between Rs. 30 crore and Rs. 80 crore, the fund seeks to bridge the ‘funding gap’ that often prevents mid-sized Indian firms from scaling up to compete with global healthcare giants.
The investment strategy is surgically focused on high-value segments, including diagnostics, cardiovascular devices, and advanced imaging components like MRI and CT scanners. Over the next two to three years, the SEBI-approved fund plans to back 10 to 12 high-potential companies. This move is expected to transform India from a net importer into a global manufacturing hub, reducing the trade deficit and lowering healthcare costs for the domestic population.
A significant feature of this initiative is its synergy with the union government’s ‘Make in India’ vision. MedArtha Capital has applied for nearly 50 per cent of its corpus, approximately Rs. 500 crore, from the Centre’s Rs. 1 lakh crore Research, Development and Innovation (RDI) scheme. This public-private partnership model is designed to de-risk Indian innovation, signalling to international markets that domestic MedTech products are high-quality and investment-ready.
Beyond capital infusion, the fund aims to build robust contract development and manufacturing organizations (CDMOs). For manufacturing hubs like Ernakulam, this is a game-changer. It allows smaller innovators to utilize professional manufacturing facilities without the prohibitive cost of building their own factories. This infrastructure support is seen as essential for moving sophisticated Indian-made devices from the design phase to mass production.
However, Dr. Satheesh Kumar emphasizes that the fund’s long-term success will hinge on more than just money. "For this Rs. 1,000 crore to truly transform the landscape, it must be paired with faster, more transparent regulatory pathways and stronger market access”, he opined. Ensuring that Indian-made life-saving equipment becomes the first choice for domestic hospitals is a critical hurdle that requires sustained policy support alongside financial investment.
Ultimately, the eight-year lifecycle of MedArtha Capital represents a bold declaration of India’s technological maturity. By fostering a globally competitive ecosystem, the initiative aims to position India, and industrial centres like Kerala, as a central nerve centre for medical innovation. If successful, this fund will not only secure India’s healthcare supply chain but also establish the ‘Make in India’ brand as a hallmark of excellence in global medical technology.
|